中德临床肿瘤学杂志（英文版）2005，Vol.4Issue(6)：330-333,4.
抗病毒治疗对合并肝炎肝癌术后的影响
Role of Antivirus Therapy in Treatment of Hepatocellular Carcinoma with Chronic Hepatitis B Infection
摘要
Abstract
Objective: To observe the recurrence and prognosis of hepatocellular carcinoma (HCC) patients coexisting with chronic hepatitis B infection with active virus replication after receiving antivirus therapy using lamivudine and thymosin α1 (Tα1) postoperatively. Methods: From Jan. 2000 to Dec. 2003,70 patients with HCC coexisting chronic hepatitis B infection with active virus replication were prospectively divided into two groups: control group (n=35) received hepatectomy only; treatment group (n=35)received hepatectomy and lamivudine plus Tα1 therapy postoperatively. The suppression of HBV-DNA,HBeAg seroconverted rate, tumor recurrent rate and the median survival for the two groups were observed and calculated. Results: In treatment group and control group, the 2-year HBV-DNA suppression rate was 100% vs. 4% (P=0.0000); HBeAg seroconverted rate was 73.0% vs. 7.5% (P＜0.05); the recurrent rate was 10.0 vs 6.5 months (P=0.0032); the median survival time was 12.5 vs. 6.0 months (P=0.0023),respectively. Conclusion: Antivirus therapy using lamivudine and Tα1 postoperatively may suppress the HBV reaction, delay the recurrent time and prolong the survival for HCC patients coexisting chronic HBV infection with active virus replication.关键词
原发性肝癌/肝炎/复发/抗病毒治疗Key words
hepatocellular carcinoma/hepatitis/recurrence/antivirus therapy分类
医药卫生引用本文复制引用
程树群,丁光辉,石洁,郭卫星,赵玉祥,沈丽,梁丽琼,吴孟超..抗病毒治疗对合并肝炎肝癌术后的影响[J].中德临床肿瘤学杂志（英文版）,2005,4(6):330-333,4.基金项目
Supported in part by Shanghai Science and Technology Committee (Project No: 04QMH1408) and Shanghai Hospital New Star Plan (2002). （Project No: 04QMH1408）
